OMS ElectroImmunotherapy: Additional Phase I data

The open-label, U.S. Phase II OMS-I110 trial in 14 evaluable patients with MCC showed that ImmunoPulse IL-12 led to an increase in IL-12 protein levels in tumor biopsy samples in 79% of patients about...